Webinar
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can achieve price premiums over benchmarks.
Looking ahead, a recent policy to establish a Category C drug list is energizing the pharma industry, potentially providing coverage through government-guided commercial insurance for high-cost, innovative products not included in the NRDL.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will evaluate the impact of the value-rating system on NRDL negotiations, explore successful outcomes across therapeutic areas and introduce potential commercial pathways to inform strategic go-to-market planning for novel therapies.
Key Topics
- Overview of the 2024 China NRDL update: Changes, trends and outcomes
- Case studies across oncology, rare diseases and chronic conditions: Learnings from successful products
- Introduce the Category C and potential commercial access in the future
- Recommendation and outlook for future China pricing and access opportunities
